Table 3.
Univariate and multivariable competing risk analysis for CVD-related death among patients with BC in the training cohort.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | ||||
| <65 | Reference | Reference | ||
| 65–74 | 2.82 (2.64–3.02) | <0.001 | 2.89 (2.70–3.10) | <0.001 |
| 75–84 | 5.40 (5.07–5.74) | <0.001 | 5.55 (5.22–5.91) | <0.001 |
| ≥85 | 7.73 (7.23–8.27) | <0.001 | 8.00 (7.45–8.55) | <0.001 |
| Sex | ||||
| Male | Reference | Reference | ||
| Female | 0.79 (0.76–0.83) | <0.001 | 0.68 (0.65–0.71) | <0.001 |
| Race | ||||
| White | Reference | Reference | ||
| Black | 0.79 (0.71–0.85) | <0.001 | 0.97 (0.88–1.06) | 0.527 |
| Others | 0.76 (0.69–0.84) | <0.001 | 0.78 (0.71–0.86) | <0.001 |
| Marital status | ||||
| Married | Reference | Reference | ||
| Single/other | 1.25 (1.20–1.29) | <0.001 | 1.22 (1.17–1.27) | <0.001 |
| Primary site | ||||
| C67.0-Trigone of bladder | Reference | Reference | ||
| C67.1-Dome of bladder | 1.08 (0.96,1.22) | 0.185 | 1.02 (0.90–1.14) | 0.789 |
| C67.2-Lateral wall of bladder | 1.07 (0.98,1.15) | 0.123 | 1.04 (0.96–1.12) | 0.392 |
| C67.3-Anterior wall of bladder | 1.17 (1.02,1.34) | 0.021 | 1.09 (0.95–1.25) | 0.213 |
| C67.4-Posterior wall of bladder | 1.14 (1.04,1.25) | 0.005 | 1.05 (0.96–1.15) | 0.318 |
| C67.5-Bladder neck | 1.08 (0.95,1.23) | 0.237 | 1.03 (0.90–1.17) | 0.695 |
| C67.6-Ureteric orifice | 1.03 (0.92,1.15) | 0.613 | 1.03 (0.92–1.15) | 0.656 |
| C67.7-Urachus | 0.21 (0.10,0.56) | 0.002 | 0.73 (0.27–1.94) | 0.524 |
| C67.8-Overlapping lesion of bladder | 1.00 (0.91,1.09) | 0.996 | 1.01 (0.92–1.10) | 0.891 |
| C67.9-Bladder, NOS | 0.99 (0.91,1.07) | 0.757 | 0.96 (0.89–1.04) | 0.311 |
| Histologic type | ||||
| Transitional cell carcinoma | Reference | Reference | ||
| Squamous cell carcinoma | 0.60 (0.51,0.71) | <0.001 | 0.73 (0.61–0.86) | <0.001 |
| Adenocarcinoma | 0.46 (0.34,0.62) | <0.001 | 0.71 (0.52–0.96) | 0.028 |
| Other and unclassified carcinoma | 0.53 (0.43,0.65) | <0.001 | 0.82 (0.67–1.01) | 0.064 |
| Tumor grade | ||||
| I | Reference | Reference | ||
| II | 1.02 (0.97,1.08) | 0.459 | 0.99 (0.94–1.04) | 0.705 |
| III | 0.95 (0.89,1.00) | 0.071 | 0.92 (0.86–0.98) | 0.009 |
| IV | 0.79 (0.75,0.84) | <0.001 | 0.77 (0.72–0.82) | <0.001 |
| Summary stage | ||||
| In situ | Reference | Reference | ||
| Localized | 0.95 (0.91,0.98) | 0.004 | 0.90 (0.86–0.94) | <0.001 |
| Regional | 0.49 (0.45,0.53) | <0.001 | 0.60 (0.55–0.66) | <0.001 |
| Distant | 0.22 (0.19,0.27) | <0.001 | 0.29 (0.24–0.35) | <0.001 |
| Surgery | ||||
| No | Reference | |||
| Yes | 1.07 (0.97,1.19) | 0.183 | ||
| Radiotherapy | ||||
| No | Reference | Reference | ||
| Yes | 0.82 (0.76,0.90) | <0.001 | 0.96 (0.87–1.05) | 0.344 |
| Chemotherapy | ||||
| No | Reference | Reference | ||
| Yes | 0.57 (0.54,0.60) | <0.001 | 0.77 (0.73–0.82) | <0.001 |